Skip to main content

Barriers to the optimal use of anticoagulants after orthopaedic surgery

Archives of Orthopaedic and Trauma Surgery volume 129, pages 1441–1445 (2009)Cite this article

Abstract

Venous thromboembolism (VTE) and the consequent morbidity and mortality associated with this condition continue to be a problem following orthopaedic surgery. The vast majority of patients undergoing orthopaedic surgery receive some form of thromboprophylaxis. However, the use of inappropriate thromboprophylaxis is an important factor which may explain why the clinical burden of VTE is still considerable. Barriers to the use of appropriate thromboprophylaxis include the belief by some surgeons that pharmacological thromboprophylaxis increases the risk of bleeding and the asymptomatic nature of deep vein thrombosis. In addition, in patients at risk of VTE, thromboprophylaxis should be given beyond the standard duration recommended in international or national guidelines, and many surgeons have concerns about adherence and adverse events in the outpatient setting. Furthermore, currently available anticoagulants have drawbacks, including the need for monitoring, or a subcutaneous route of administration. The introduction and implementation of multi-faceted and integrated approaches to thromboprophylaxis could improve adherence with current guidelines, extend appropriate thromboprophylaxis according to risk factors, and improve patient outcomes in this setting. In addition, the development of new anticoagulants with more convenient administration regimens and no need for monitoring may help to achieve these objectives.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Anderson FA Jr, White K (2002) Prolonged prophylaxis in orthopedic surgery: insights from the United States. Semin Thromb Hemost 28(Suppl 3):43–46

    PubMed  Article  Google Scholar 

  2. Arnold DM, Kahn SR, Shrier I (2001) Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 120:1964–1971

    PubMed  Article  CAS  Google Scholar 

  3. Aujesky D, Guignard E, Pannatier A et al (2002) Pharmacological thromboembolic prophylaxis in a medical ward: room for improvement. J Gen Intern Med 17:788–791

    PubMed  Article  Google Scholar 

  4. Bergqvist D (1993) Long-term prophylaxis following orthopedic surgery. Haemostasis 23(Suppl 1):27–31

    PubMed  Google Scholar 

  5. Bergqvist D, Jonsson B (1999) Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement. Value Health 2:288–294

    PubMed  Article  CAS  Google Scholar 

  6. Blackburn J, Schumock G, Bauman J (2005) Barriers to appropriate anticoagulation with warfarin in orthopedic surgery. J Thromb Haemost 3(Suppl 1):PO430

    Google Scholar 

  7. Borris LC, Breindahl M, Ryge C et al (2007) Prothrombin fragment 1+2 in urine as an indicator of sustained coagulation activation after total hip arthroplasty. Thromb Res 121:369–376

    PubMed  Article  CAS  Google Scholar 

  8. Brenkel IJ, Cook RE (2003) Thromboprophylaxis in patients undergoing total hip replacement. Hosp Med 64:281–287

    PubMed  CAS  Google Scholar 

  9. Brenkel IJ, Hyers TM (2004) Thromboprophylaxis in patients undergoing hip replacement: a survey of British orthopaedic surgeons. J Bone Joint Surg Br 87(Suppl III):277

    Google Scholar 

  10. Caprini JA, Hyers TM (2006) Compliance with antithrombotic guidelines. Manag Care 15:49–60, 66

    Google Scholar 

  11. Cohen AT, Alikhan R, Arcelus JI et al (2005) Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 94:750–759

    PubMed  Google Scholar 

  12. Cohen AT, Tapson VF, Bergmann JF et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387–394

    PubMed  Article  Google Scholar 

  13. Cohn SL, Adekile A, Mahabir V (2006) Improved use of thromboprophylaxis for deep vein thrombosis following an educational intervention. J Hosp Med 1:331–338

    PubMed  Article  Google Scholar 

  14. Dahl OE (1999) Mechanisms of hypercoagulability. Thromb Haemost 82:902–906

    PubMed  CAS  Google Scholar 

  15. Dahl OE (2000) Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now? Haemostasis 30(Suppl 2):101–105

    PubMed  Google Scholar 

  16. Dahl OE (2004) Orthopaedic surgery as a model for drug development in thrombosis. Drugs 64(Suppl 1):17–25

    PubMed  Article  Google Scholar 

  17. Eriksson BI, Quinlan DJ (2006) Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 66:1411–1429

    PubMed  Article  CAS  Google Scholar 

  18. Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775

    PubMed  Article  CAS  Google Scholar 

  19. Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:338S–400S

    PubMed  Article  CAS  Google Scholar 

  20. Gross M, Anderson DR, Nagpal S et al (1999) Venous thromboembolism prophylaxis after total hip or knee arthroplasty: a survey of Canadian orthopedic surgeons. Can J Surg 42:457–461

    PubMed  CAS  Google Scholar 

  21. Haas S (2003) Medical indications and considerations for future clinical decision making. Thromb Res 109:S31

    PubMed  Article  CAS  Google Scholar 

  22. Haas S, Schellong S (2007) New anticoagulants: from bench to bedside. Hamostaseologie 27:41–47

    PubMed  CAS  Google Scholar 

  23. Kakkar VV, Cohen AT, Edmonson RA et al (1993) Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 341:259–265

    PubMed  Article  CAS  Google Scholar 

  24. Kakkar AK, Levine M, Pinedo HM et al (2003) Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 8:381–388

    PubMed  Article  Google Scholar 

  25. Kakkar AK, Davidson BL, Haas SK (2004) Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost 2:221–227

    PubMed  Article  CAS  Google Scholar 

  26. Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39

    PubMed  Article  CAS  Google Scholar 

  27. Koch A, Ziegler S, Breitschwerdt H et al (2001) Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res 102:295–309

    PubMed  Article  CAS  Google Scholar 

  28. Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2886

    PubMed  Article  CAS  Google Scholar 

  29. Learhinan ER, Alderman CP (2003) Venous thromboembolism prophylaxis in a South Australian teaching hospital. Ann Pharmacother 37:1398–1402

    PubMed  Article  Google Scholar 

  30. Levine MN, Raskob G, Beyth RJ et al (2004) Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:287S–310S

    PubMed  Article  CAS  Google Scholar 

  31. Lieberman JR, Hsu WK (2005) Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 87:2097–2112

    PubMed  Article  Google Scholar 

  32. Mismetti P, Laporte S, Darmon JY et al (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88:913–930

    PubMed  Article  CAS  Google Scholar 

  33. Rosendaal FR (1999) Venous thrombosis: a multicausal disease. Lancet 353:1167–1173

    PubMed  Article  CAS  Google Scholar 

  34. Salvati EA, Pellegrini VD Jr, Sharrock NE et al (2000) Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg Am 82:252–270

    PubMed  CAS  Google Scholar 

  35. Scaglione L, Piobbici M, Pagano E et al (2005) Implementing guidelines for venous thromboembolism prophylaxis in a large Italian teaching hospital: lights and shadows. Haematologica 90:678–684

    PubMed  Google Scholar 

  36. Schunemann HJ, Cook D, Grimshaw J et al (2004) Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:688S–696S

    PubMed  Article  Google Scholar 

  37. Select Committee on Health of the United Kingsom (2005) Second Report. Hansard

  38. Tapson VF, Goldhaber SZ (2003) Failure to provide prophylaxis for deep vein thrombosis: results from the DVT-Free registry. Blood 102:322a

    Google Scholar 

  39. Tooher R, Middleton P, Pham C et al (2005) A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg 241:397–415

    PubMed  Article  Google Scholar 

  40. Turpie AG (2007) Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 27:1238–1247

    PubMed  Article  CAS  Google Scholar 

  41. Vallano A, Arnau De Bolos JM et al (2004) Use of venous thromboprophylaxis and adherence to guideline recommendations: a cross-sectional study. Thromb J 2:3

    PubMed  Article  Google Scholar 

  42. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients undergoing surgery (2007) National Institute of Health and Clinical Excellence Guideline 46

  43. Walker N, Rodgers A, Gray H (2002) Changing patterns of pharmacological thromboprophylaxis use by orthopaedic surgeons in New Zealand. ANZ J Surg 72:335–338

    PubMed  Article  Google Scholar 

  44. Wan S, Ting J, Olsen A et al (2003) Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia. ANZ J Surg 73:826–829

    PubMed  Article  Google Scholar 

  45. Warwick D, Friedman RJ, Agnelli G et al (2007) Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 89:799–807

    PubMed  Article  CAS  Google Scholar 

  46. Zaw HM, Osborne IC, Pettit PN et al (2002) Risk factors for venous thromboembolism in orthopedic surgery. Isr Med Assoc J 4:1040–1042

    PubMed  Google Scholar 

Download references

Acknowledgments

The author would like to acknowledge Dr Carole Mongin-Bulewski, who provided editorial assistance with funding from Bayer HealthCare AG.

Author information

Affiliations

  1. Department of Orthopaedics, Århus University Hospital, Nørrebrogade 44, 8000, Århus C, Denmark

    L. C. Borris

Authors
  1. L. C. Borris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. C. Borris.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Borris, L.C. Barriers to the optimal use of anticoagulants after orthopaedic surgery. Arch Orthop Trauma Surg 129, 1441–1445 (2009). https://doi.org/10.1007/s00402-008-0765-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00402-008-0765-9

Keywords

  • Factor Xa inhibitors
  • Venous thromboembolism
  • Orthopaedic surgery
  • Deep vein thrombosis
  • Pulmonary embolism
  • Risk factor stratification